Genmab — Maj 2019

[Sukkeralf]

Iconic lavede aftale med Zymeworks i går og udlicensierede til Exelixis i dag. Igen vel en udløber af at tisotumab vedotin gør det godt

[saltpeter]

Jeg ved ikke helt om den er listet her,Bryan Garnier :GENMAB: SC Darzalex should make isatuximab obsolete | BUY | DKK1300(+17%)
GENMAB - BUY | DKK1300(+17%)
SC Darzalex should make isatuximab obsolete

Isatuximab’s data show no clear superiority over Dara
Subcutaneous Darzalex: a better Darzalex in every way

[saltpeter]

Just a moment...

(www.researchpool.com)

[E_L]

After discount row, NICE finally says yes to first line Revlimid https://www.pmlive.com/pharma_news/after_discount_row,_nice_finally_says_yes_to_first_line_revlimid_1288450

[E_L]

"The decision is a breakthrough for Celgene in England, where newer entrants – most notably Janssen’s Darzalex – are now making rapid in-roads."

[bongobob]

@gentogen efterlyste CD33xCD3 Duobody. Den er nævnt i J&J slides EL linkede til og nu også på Gemab produkt side JNJ-67571244. http://www.genmab.com/product-pipeline/products-in-development

[bongobob]

Vi er oppe på 6 stk. JJ duobody i klinikken!

[bongobob]

JNJ-63898081 er også ny for mig?

[E_L]

Also for me @bongobob @gentogen ! I was only aware of 4 of them, nice surprise!

[E_L]

JNJ-63898081 is in the clinic and recruiting already... prostate cancer https://clinicaltrials.gov/ct2/show/NCT03926013

[bongobob]

Yes in the JJ slides it is marked as undisclosed target CD3 bispecific

[E_L]

and the other one : A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) https://clinicaltrials.gov/ct2/show/NCT03915379

[Sukkeralf]

Tak bongobob - på Adis Insight stod Janssen som fuld ejer af JNJ-67571244. Dejligt at Janssen rykker

[E_L]

it was on this May Genmab factsheet also https://ir.genmab.com/static-files/2541bd13-afb9-4c9d-91c4-7ec4c3b0fdc6 , not sure if this was part of the results presentation, but had not seen it

[E_L]

Dr Durie ASCO 2019: The Myeloma Top 10 https://www.myeloma.org/hope-blog/asco-2019-abstracts-released-myeloma-top-10

[E_L]

Note on 8004 "The safety and added efficacy of isatuximab in this setting is thus demonstrated, although the magnitude of added benefit is not as impressive as one might have expected. "

[E_L]

can't believe you have a holiday again in Denmark...

[lahn1]

@EL We need one after last nights party

[Sukkeralf]

E L abstracts 8004 - the last lines: The safety and added efficacy of isatuximab in this setting is thus demonstrated, although the magnitude of added benefit is not as impressive as one might have expected.

[E_L]

lol